Medicinova Stock Price To Sales

MNOV Stock

USD 2.13 0.13 6.50%

MediciNova fundamentals help investors to digest information that contributes to MediciNova's financial success or failures. It also enables traders to predict the movement of MediciNova Stock. The fundamental analysis module provides a way to measure MediciNova's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MediciNova stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	84.60	107.43

Price To Sales Ratio is likely to climb to 107.43 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

MediciNova Company Price To Sales Analysis

MediciNova's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current MediciNova Price To Sales

104.47 X

Most of MediciNova's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MediciNova is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

MediciNova Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for MediciNova is extremely important. It helps to project a fair market value of MediciNova Stock properly, considering its historical fundamentals such as Price To Sales. Since MediciNova's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MediciNova's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MediciNova's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Retained Earnings	Total Liab	Net Debt	Accounts Payable	Short Term Investments	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Short Term Debt	Intangible Assets	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Net Receivables	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.75	0.0	-0.86	0.17	0.24	0.99	0.9	-0.51	0.03	0.33	-0.27	-0.47	0.96	0.88	-0.82	-0.2	0.93	0.93	0.56
Total Stockholder Equity	1.0		-0.71	-0.05	-0.85	0.16	0.26	1.0	0.9	-0.45	0.04	0.29	-0.27	-0.42	0.97	0.89	-0.8	-0.14	0.93	0.93	0.54
Retained Earnings	-0.75	-0.71		-0.49	0.56	-0.27	-0.19	-0.65	-0.86	0.89	-0.13	-0.54	-0.03	0.91	-0.61	-0.68	0.61	0.29	-0.57	-0.56	-0.51
Total Liab	0.0	-0.05	-0.49		0.11	0.16	-0.1	-0.09	0.13	-0.77	0.25	0.07	0.61	-0.76	-0.19	-0.17	0.23	0.15	-0.23	-0.23	-0.21
Net Debt	-0.86	-0.85	0.56	0.11		-0.28	0.12	-0.86	-0.73	0.3	0.06	-0.39	0.29	0.28	-0.86	-0.79	0.74	0.32	-0.84	-0.85	-0.57
Accounts Payable	0.17	0.16	-0.27	0.16	-0.28		-0.11	0.15	0.29	-0.2	-0.08	0.4	-0.04	-0.19	0.19	0.3	-0.39	-0.28	0.07	0.06	0.27
Short Term Investments	0.24	0.26	-0.19	-0.1	0.12	-0.11		0.26	0.27	-0.07	-0.3	-0.09	-0.39	-0.04	0.24	0.29	-0.37	0.1	0.23	0.22	0.25
Total Current Assets	0.99	1.0	-0.65	-0.09	-0.86	0.15	0.26		0.87	-0.39	0.02	0.25	-0.29	-0.36	0.98	0.88	-0.79	-0.11	0.93	0.93	0.53
Common Stock	0.9	0.9	-0.86	0.13	-0.73	0.29	0.27	0.87		-0.61	0.11	0.49	-0.21	-0.62	0.88	0.92	-0.77	-0.18	0.73	0.72	0.63
Property Plant Equipment	-0.51	-0.45	0.89	-0.77	0.3	-0.2	-0.07	-0.39	-0.61		-0.22	-0.41	-0.3	0.96	-0.32	-0.37	0.31	0.17	-0.3	-0.3	-0.25
Current Deferred Revenue	0.03	0.04	-0.13	0.25	0.06	-0.08	-0.3	0.02	0.11	-0.22		-0.31	0.76	-0.27	-0.06	-0.16	0.39	0.39	-0.19	-0.16	-0.55
Good Will	0.33	0.29	-0.54	0.07	-0.39	0.4	-0.09	0.25	0.49	-0.41	-0.31		-0.41	-0.39	0.37	0.6	-0.58	-0.82	0.32	0.3	0.83
Short Term Debt	-0.27	-0.27	-0.03	0.61	0.29	-0.04	-0.39	-0.29	-0.21	-0.3	0.76	-0.41		-0.35	-0.4	-0.51	0.68	0.52	-0.46	-0.43	-0.77
Intangible Assets	-0.47	-0.42	0.91	-0.76	0.28	-0.19	-0.04	-0.36	-0.62	0.96	-0.27	-0.39	-0.35		-0.29	-0.35	0.27	0.12	-0.25	-0.25	-0.21
Net Tangible Assets	0.96	0.97	-0.61	-0.19	-0.86	0.19	0.24	0.98	0.88	-0.32	-0.06	0.37	-0.4	-0.29		0.94	-0.84	-0.19	0.91	0.92	0.65
Capital Surpluse	0.88	0.89	-0.68	-0.17	-0.79	0.3	0.29	0.88	0.92	-0.37	-0.16	0.6	-0.51	-0.35	0.94		-0.9	-0.37	0.82	0.82	0.83
Deferred Long Term Liab	-0.82	-0.8	0.61	0.23	0.74	-0.39	-0.37	-0.79	-0.77	0.31	0.39	-0.58	0.68	0.27	-0.84	-0.9		0.53	-0.84	-0.82	-0.85
Net Receivables	-0.2	-0.14	0.29	0.15	0.32	-0.28	0.1	-0.11	-0.18	0.17	0.39	-0.82	0.52	0.12	-0.19	-0.37	0.53		-0.33	-0.31	-0.68
Net Invested Capital	0.93	0.93	-0.57	-0.23	-0.84	0.07	0.23	0.93	0.73	-0.3	-0.19	0.32	-0.46	-0.25	0.91	0.82	-0.84	-0.33		1.0	0.61
Net Working Capital	0.93	0.93	-0.56	-0.23	-0.85	0.06	0.22	0.93	0.72	-0.3	-0.16	0.3	-0.43	-0.25	0.92	0.82	-0.82	-0.31	1.0		0.58
Capital Stock	0.56	0.54	-0.51	-0.21	-0.57	0.27	0.25	0.53	0.63	-0.25	-0.55	0.83	-0.77	-0.21	0.65	0.83	-0.85	-0.68	0.61	0.58

Click cells to compare fundamentals

MediciNova Price To Sales Historical Pattern

Today, most investors in MediciNova Stock are looking for potential investment opportunities by analyzing not only static indicators but also various MediciNova's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of MediciNova price to sales as a starting point in their analysis.

MediciNova Price To Sales

Timeline

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict MediciNova

Price To Sales Ratio Over Time

MediciNova Price To Sales Ratio

Price To Sales Ratio

107.43

At this time, MediciNova's Price To Sales Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, MediciNova has a Price To Sales of 104 times. This is 388.17% higher than that of the Biotechnology sector and 6.16% higher than that of the Health Care industry. The price to sales for all United States stocks is notably lower than that of the firm.

MediciNova Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MediciNova's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MediciNova could also be used in its relative valuation, which is a method of valuing MediciNova by comparing valuation metrics of similar companies.

MediciNova is currently under evaluation in price to sales category among its peers.

MediciNova Current Valuation Drivers

We derive many important indicators used in calculating different scores of MediciNova from analyzing MediciNova's financial statements. These drivers represent accounts that assess MediciNova's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of MediciNova's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	290.9M	233.6M	130.2M	100.5M	90.5M	99.2M
Enterprise Value	227.5M	173.8M	58.9M	82.2M	74.0M	82.8M

MediciNova ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, MediciNova's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to MediciNova's managers, analysts, and investors.

Environmental

Governance

Social

MediciNova Fundamentals

	Return On Equity	-0.13
	Return On Asset	-0.0951
	Operating Margin	(9.82) %
	Current Valuation	62.39 M
	Shares Outstanding	49.05 M
	Shares Owned By Insiders	2.98 %
	Shares Owned By Institutions	21.30 %
	Number Of Shares Shorted	182.2 K
	Price To Earning	(24.69) X
	Price To Book	1.90 X
	Price To Sales	104.47 X
	Revenue	1000 K
	Gross Profit	4.04 M
	EBITDA	(9.88 M)
	Net Income	(8.57 M)
	Cash And Equivalents	65.23 M
	Cash Per Share	1.33 X
	Total Debt	215.93 K
	Debt To Equity	0.01 %
	Current Ratio	17.17 X
	Book Value Per Share	1.27 X
	Cash Flow From Operations	(7.43 M)
	Short Ratio	11.20 X
	Earnings Per Share	(0.21) X
	Price To Earnings To Growth	(0.94) X
	Target Price	8.0
	Number Of Employees	13
	Beta	0.77
	Market Capitalization	104.47 M
	Total Asset	66.27 M
	Retained Earnings	(415.7 M)
	Working Capital	47.9 M
	Current Asset	22.73 M
	Current Liabilities	1.49 M
	Net Asset	66.27 M

About MediciNova Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze MediciNova's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MediciNova using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MediciNova based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for MediciNova Stock Analysis

When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC